id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-342084-fbtx7rwi	Ceccarelli, Giancarlo	IS TEICOPLANIN A COMPLEMENTARY TREATMENT OPTION FOR COVID-19? THE QUESTION REMAINS	2020-05-23		.txt	text/plain	643	41	47	We read with great interest the editorial by Baron Coronavirus (MERS-CoV), but also Ebola virus, influenza A and B viruses, and feline infectious peritonitis virus (FIPV), were reported as potential targets of teicoplanin and its chemical derivatives. Based on the aforementioned, teicoplanin has been used either as a potential antiviral agent and treatment of possible Staphylococcus aureus superinfection in our critical patients with severe SARS-CoV-2 pneumonia, since this latter may represent a major complication of respiratory viral infections. Moreover, a recent study showed that teicoplanin potently prevents the entrance of SARS-CoV2 into the cytoplasm with an IC50 of only 1.66 μM which is much lower than the routine trough serum drug concentration (approximately 7-8 μM/L). Therefore, the routinely-used teicoplanin doses adopted in our series might be considered as potentially adequate for treatment of patients with SARS-CoV2 infection. Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)	./cache/cord-342084-fbtx7rwi.txt	./txt/cord-342084-fbtx7rwi.txt